Black Diamond Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Black Diamond Therapeutics

07/08/2024 15:38

* Black Diamond Therapeutics Inc  BDTX.OQ   BDTX.O  is
expected
to show no change in quarterly revenue when it reports 
results on November 4 (estimated) for the period ending
September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Black Diamond
Therapeutics Inc
is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 10.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $13.50​, above​ its last closing price
of $5.01. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.38       -0.39      -0.36     Beat    7
 Mar. 31 2024  -0.42       -0.43      -0.35     Beat    19.5
 Dec. 31 2023  -0.45       -0.47      -0.34     Beat    27​
 Sep. 30 2023  -0.44       -0.49      -0.45     Beat    7.5
 ​​Jan.        -0.54       -0.54      -0.52     Beat    3
 1 0001                                                 
 Mar. 31 2023  -0.61       -0.61      -0.57     Beat    6.2​
 Dec. 31 2022              -0.63      -0.59     Beat    6
 Sep. 30 2022  -0.64       -0.64      -0.60     Beat    6.3
 This summary was machine generated August 7 at 14:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)